"Maintain Your Brain" study shows how a tailored online program can improve cognition and lower dementia risk—discover how simple lifestyle changes could protect your brain as you age.

Peter Alexander, now 56 and living in Northern Ireland, never expected to be diagnosed with the memory robbing disorder when ...

An online program aimed at improving diet, exercise and other modifiable risk factors for dementia has resulted in better cognition in older adults, Australian research has found.

Beijing has rolled out policy frameworks aimed at expanding eldercare and dementia services for an aging China but it is ...

There are two kinds of risk factors for dementia: non-modifiable and modifiable. Non-modifiable risk factors are ones that cannot be changed or eliminated, like aging, family history and genetics.

Known for its "laidback, egalitarian" office environment, how does Australia's work culture compare to the rest of the world? From morning coffee runs to jokes with colleagues, Australia's work ...

Shaving off a massive AU$120 over the first six months, Tangerine's Fixed Wireless Speedy plan is hard to pass up. This plan claims to reach between 200Mbps and 250Mbps during the busy evening ...

With plenty of options, deciding the best internet plan for you may take some ... Very few internet service providers in Australia continue to support ADSL, as the copper cables used have been ...

Find out about the free, family friendly events on in Melbourne on 26 January. Victorians are invited to events to respect, reflect and celebrate Australia Day 2025, including family-friendly ...

With so many landmarks to see in Australia, it can be difficult knowing where to start. Here are 10 of the best attractions Down Under One of Australia’s definitive wonders, this is a dazzling ...

The Montreal Cognitive Assessment (MoCA) is a test used to detect mild cognitive decline and early signs of dementia. It can help identify people at risk of Alzheimer's disease and screen for ...

Progress in dementia research and clinical care has continued to accelerate in 2024. Monoclonal antibody anti-amyloid immunotherapies (AATs) have been approved for clinical use for patients with mild ...